Division of Abbott Laboratories Inc.
Latest From AdnaGen AG
Diagnostics, orthopedics, and cardiovascular device companies are among those that wait until November to report their results for the quarter that ended at the end of September. Medtech Insight’s Earnings Winners & Losers highlights some of the companies that had news to celebrate, and a few that were disappointed with the quarter.
Liquid biopsies – carrying out diagnostic tests on liquid samples such as blood or urine rather than on tissue biopsy material – look set to revolutionize the management of cancer patients. This area has recently captured the interest of a growing number of diagnostic players, both big and small, and spawned the development of different approaches to liquid biopsy. This article marks out who's who in this increasingly busy landscape and the key technologies that are showing promise, and looks at the obstacles that companies are facing.
A multibillion-dollar market is on the way for liquid biopsy, which allows the measurement of markers present in biological fluids, a repeatable method of disease diagnosis that could replace some invasive biopsies and allow clinicians access to tissues that have been inaccessible with current methods. Within this dynamic field, ANGLE PLC is coming closer to clinical application market readiness with its circulating tumor cell harvesting technology, as CEO Andrew Newland explains.
The US companion diagnostics sector is predicted to grow from $1.6 billion to $6.2 billion between 2015 and 2021, a CAGR of 25.3%, outpacing the IVD market growth fivefold. This rapid growth will be driven by the development of new targeted pharmaceutical products and moves by the FDA to quickly approve new treatments and diagnostics together.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Abbott Laboratories Inc.
- Senior Management
Alexander P Weis, PhD, CEO
Siegfried Hauch, Dir., R&D
- Contact Info
Phone: (49) 511 72595050
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.